MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model
Metrics: PDF 2552 views | HTML 2529 views | ?
Wenying Yan1,2,3, Lihua Xu4,5, Zhandong Sun1, Yuxin Lin1, Wenyu Zhang1, Jiajia Chen6, Shaoyan Hu4, Bairong Shen1
1Center for Systems Biology, Soochow University, Suzhou, 215006, China
2Taicang Center for Translational Bioinformatics, Taicang 215400, China
3The 100th Hospital of PLA, Suzhou 215007, China
4Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, China
5Department of Pediatrics, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222002, China
6School of Chemistry, Biology and Material Engineering, Suzhou University of Science and Technology, Suzhou 215011, China
Bairong Shen, e-mail: [email protected]
Keywords: microRNA biomarkers, transcription factor, pediatric acute myeloid leukemia, bioinformatics model, microRNA regulatory network
Received: March 27, 2015 Accepted: June 19, 2015 Published: July 01, 2015
Acute myeloid leukemia (AML) in children is a complex and heterogeneous disease. The identification of reliable and stable molecular biomarkers for diagnosis, especially early diagnosis, remains a significant therapeutic challenge. Aberrant microRNA expression could be used for cancer diagnosis and treatment selection. Here, we describe a novel bioinformatics model for the prediction of microRNA biomarkers for the diagnosis of paediatric AML based on computational functional analysis of the microRNA regulatory network substructure. microRNA-196b, microRNA-155 and microRNA-25 were identified as putative diagnostic biomarkers for pediatric AML. Further systematic analysis confirmed the association of the predicted microRNAs with the leukemogenesis of AML. In vitro q-PCR experiments showed that microRNA-155 is significantly overexpressed in children with AML and microRNA-196b is significantly overexpressed in subgroups M4–M5 of the French-American-British classification system. These results suggest that microRNA-155 is a potential diagnostic biomarker for all subgroups of paediatric AML, whereas microRNA-196b is specific for subgroups M4–M5.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.